Globus Medical price target raised to $71 from $67 at Canaccord

Canaccord raised the firm’s price target on Globus Medical to $71 from $67 and keeps a Buy rating on the shares. The firm noted during the Q3 call, GMED increased its 2023 revenue guidance while reaffirming non-GAAP EPS guidance.